Methods and Pharmaceutical Compositions for the Treatment of FGFR3-RELATED Chondrodysplasias
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,257,232 | Methods and Pharmaceutical Compositions for the Treatment of FGFR3-RELATED Chondrodysplasias Inserm (Institut National de la Sante et de la Recherche Medicale), Universite de Paris, Fondation Imagine, Assistance Publique-Hopitaux de Paris (Aphp) and Universidad de Granada In force · High confidence | Inserm (Institut National de la Sante et de la Recherche Medicale), Universite de Paris, Fondation Imagine, Assistance Publique-Hopitaux de Paris (Aphp) and Universidad de Granada | In force | High confidence | ||
| US 11,951,090 | Methods and Pharmaceutical Compositions for the Treatment of FGFR3-RELATED Chondrodysplasias In force · High confidence | Université Paris Cité | In force | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Fondation Imagine.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.